• 

  Alzheimer’s Drug Trials: Do Drug Companies Warn You About Your Genetic Risk?
• 

  Trojan Horse: Carrying Alzheimer’s Antibodies Into the Brain
• 

  States Propose Bills to Make Private Insurers Cover Approved Alzheimer’s Drugs, Diagnostics
• 

  Curing Alzheimer’s Disease: Magic Bullet or Magic Shotgun Blast?
• 

  Alzheon Alzheimer’s Pill Misses the Mark in Phase 3 Trial, Hints at Benefit in MCI
• 

  After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs
• 

  No Kisunla in Europe: Regulators Reject Lilly’s Alzheimer’s ‘Mab’ Drug
• 

  Might Xenon Gas Be Useful for Treating Alzheimer’s, as a New Study Suggests?
• 

  Australia Is Latest Country to Say ‘No’ to Leqembi
• 

  Remternetug: Alzheimer’s Prevention Trial Enrolls People as Young as 18
• 

  Leqembi Vs. Kisunla: An Alzheimer’s Drug Point-by-Point Comparison
• 

  Some Trial Volunteers Had Higher Risk of Brain Bleeds. Here’s Why Drugmakers Didn’t Tell Them
• 

  Axsome Asks FDA to Approve Questionable Alzheimer’s Agitation Drug
• 

  Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement
• 

  How Bad Is Fraud in Alzheimer’s Research? Q&A With Neurologist-Sleuth Matthew Schrag

Previous345Next